- Home
- UNCY vs VRCA Comparison
UNCY vs VRCA Comparison
Compare UNCY & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNCY
- VRCA
- Stock Information
- Founded
- UNCY 2016
- VRCA 2013
- Country
- UNCY United States
- VRCA United States
- Employees
- UNCY N/A
- VRCA N/A
- Industry
- UNCY Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- UNCY Health Care
- VRCA Health Care
- Exchange
- UNCY Nasdaq
- VRCA Nasdaq
- Market Cap
- UNCY 71.8M
- VRCA 43.0M
- IPO Year
- UNCY 2021
- VRCA 2018
- Fundamental
- Price
- UNCY $0.62
- VRCA $0.42
- Analyst Decision
- UNCY Strong Buy
- VRCA Hold
- Analyst Count
- UNCY 3
- VRCA 5
- Target Price
- UNCY $5.50
- VRCA $6.00
- AVG Volume (30 Days)
- UNCY 510.7K
- VRCA 243.3K
- Earning Date
- UNCY 05-16-2025
- VRCA 05-13-2025
- Dividend Yield
- UNCY N/A
- VRCA N/A
- EPS Growth
- UNCY N/A
- VRCA N/A
- EPS
- UNCY N/A
- VRCA N/A
- Revenue
- UNCY N/A
- VRCA $7,566,000.00
- Revenue This Year
- UNCY N/A
- VRCA $127.58
- Revenue Next Year
- UNCY $1,502.84
- VRCA $88.06
- P/E Ratio
- UNCY N/A
- VRCA N/A
- Revenue Growth
- UNCY N/A
- VRCA 47.66
- 52 Week Low
- UNCY $0.20
- VRCA $0.38
- 52 Week High
- UNCY $1.16
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- UNCY 51.83
- VRCA 39.53
- Support Level
- UNCY $0.59
- VRCA $0.45
- Resistance Level
- UNCY $0.66
- VRCA $0.48
- Average True Range (ATR)
- UNCY 0.03
- VRCA 0.04
- MACD
- UNCY -0.00
- VRCA -0.00
- Stochastic Oscillator
- UNCY 40.05
- VRCA 22.13
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.